
Health Dictionary
Reliable, easy-to-read patient information on common medical conditions β written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Seminoma surgery
Introduction
Overview
Overview
Surgery is the mainstay of treatment for seminoma. The feasibility of surgery depends on the stage of seminoma at diagnosis which include: radical inguinal orchiectomy, retroperitoneal lymph node dissection, salvage surgery and surgery for metastases.
Surgery
Surgery
- Surgery is usually reserved for majority of patients.The feasibility of surgery depends on the stage of seminomsat diagnosis.[1][2][3]
- The feasibility of surgery depends on the stage of seminoma at diagnosis.
- Surgery is the mainstay of treatment for seminoma which include:[4][5][6][7]
Radical Inguinal Orchiectomy
- Among patients who present with clinically advanced disease, radical orchiectomy is useful to remove the tumor prior to chemotherapy when possible.
Retroperitoneal Lymph Node Dissection
- Retroperitoneal lymph node dissection (RPLND) may be helpful for any type of seminoma that doesnβt respond to chemotherapy.[7]
- RPLND may be helpful at the same time as orchiectomy, or during other surgery.[8]
Salvage Surgery
- Among patient who dose not response to chemotherapy after orchiectomy the surgery used to remove residual disease is called salvage surgery.[9][10]
- Salvage surgery may include a bilateral RPLND.[11]
Surgery for Metastases
- Surgery may be helpful remove seminoma that metastasized to the lung, liver, brain, mediastinum or neck.
References
References
- β Batool A, Karimi N, Wu XN, Chen SR, Liu YX (May 2019). “Testicular germ cell tumor: a comprehensive review”. Cell. Mol. Life Sci. 76 (9): 1713β1727. doi:10.1007/s00018-019-03022-7. PMIDΒ 30671589.
- β Boujelbene, Noureddine; Cosinschi, Adrien; Boujelbene, Nadia; Khanfir, Kaouthar; Bhagwati, Shushila; Herrmann, Eveleyn; Mirimanoff, Rene-Olivier; Ozsahin, Mahmut; Zouhair, Abderrahim (2011). “Pure seminoma: A review and update”. Radiation Oncology. 6 (1). doi:10.1186/1748-717X-6-90. ISSNΒ 1748-717X.
- β Al-Salem, Ahmed H. (2014). “Testicular Tumors”: 505β511. doi:10.1007/978-3-319-06665-3_64.
- β Boujelbene N, Cosinschi A, Boujelbene N, Khanfir K, Bhagwati S, Herrmann E, Mirimanoff RO, Ozsahin M, Zouhair A (August 2011). “Pure seminoma: a review and update”. Radiat Oncol. 6: 90. doi:10.1186/1748-717X-6-90. PMCΒ 3163197. PMIDΒ 21819630.
- β Oldenburg J, FossΓ₯ SD, Nuver J, Heidenreich A, Schmoll HJ, Bokemeyer C, Horwich A, Beyer J, Kataja V (October 2013). “Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up”. Ann. Oncol. 24 Suppl 6: vi125β32. doi:10.1093/annonc/mdt304. PMIDΒ 24078656.
- β Carver BS, Serio AM, Bajorin D, Motzer RJ, Stasi J, Bosl GJ, Vickers AJ, Sheinfeld J (December 2007). “Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors”. J. Clin. Oncol. 25 (35): 5603β8. doi:10.1200/JCO.2007.13.6283. PMIDΒ 17998544.
- β 7.0 7.1 Lavery HJ, Bahnson RR, Sharp DS, Pohar KS (October 2009). “Management of the residual post-chemotherapy retroperitoneal mass in germ cell tumors”. Ther Adv Urol. 1 (4): 199β207. doi:10.1177/1756287209350315. PMCΒ 3126061. PMIDΒ 21789067.
- β Invalid
<ref>tag; no text was provided for refs namedpmid29487620 - β Surgery for testicular cancer. Canadian cancer society 2016. http://www.cancer.ca/en/cancer-information/cancer-type/testicular/treatment/surgery/?region=on. Accessed on March 2, 2016
- β Daneshmand S, Djaladat H, Nichols C (August 2011). “Management of residual mass in nonseminomatous germ cell tumors following chemotherapy”. Ther Adv Urol. 3 (4): 163β71. doi:10.1177/1756287211418721. PMCΒ 3175700. PMIDΒ 21969846.
- β Heidenreich A, Pfister D (August 2012). “Retroperitoneal lymphadenectomy and resection for testicular cancer: an update on best practice”. Ther Adv Urol. 4 (4): 187β205. doi:10.1177/1756287212443170. PMCΒ 3398597. PMIDΒ 22852029.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sogand Goudarzi, MD [2]
